Better Healthcare ETF: Invesco's PJP vs. Simplify's PINK

Source The Motley Fool

Key Points

  • The Invesco Pharmaceuticals ETF has delivered significantly higher 1-year total returns than the Simplify Health Care ETF.

  • The Simplify Health Care ETF operates with a lower expense ratio and follows a unique pro bono model that supports breast cancer research.

  • The Invesco Pharmaceuticals ETF maintains a concentrated portfolio of 30 pharmaceutical companies, while Simplify's fund provides broader healthcare sub-sector exposure.

  • 10 stocks we like better than Simplify Exchange Traded Funds - Simplify Health Care ETF ›

Comparing the Simplify Health Care ETF (NYSEMKT:PINK) and Invesco Pharmaceuticals ETF (NYSEMKT:PJP) reveals distinct approaches to healthcare, with PINK focusing on broad innovation through active management and PJP offering concentrated exposure to the U.S. pharmaceutical industry.

Investors seeking healthcare exposure must often choose between the stability of established pharmaceutical giants and the growth potential of medical technology. The Simplify Health Care ETF uses an active strategy to find innovators, while the Invesco Pharmaceuticals ETF tracks a rules-based index of 30 specialized companies engaged in drug research and distribution.

Snapshot (cost & size)

MetricPJPPINK
IssuerInvescoSimplify
Share price$131.04 (as of 2026-11-13)$39.98 (as of 2026-11-13)
Expense ratio0.58%0.51%
1-yr return (as of Oct. 31, 2026)36.1%22.7%
Dividend yield0.9%0.8%
Beta0.320.69
AUM$581.9 million$345.2 million

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The Simplify Health Care ETF is the more affordable option with a 0.51% expense ratio, compared to the 0.58% charged by the Invesco Pharmaceuticals ETF. The yield difference is marginal, as PJP offers a slightly higher trailing-12-month payout than PINK.

Performance & risk comparison

MetricPJPPINK
Max drawdown (5 yr)(17.5%)(18.7%)
Growth of $1,000 over 5 years (total return)$1,673$1,595

What's inside

The Simplify Health Care ETF is an actively managed fund that targets long-term capital appreciation by investing in healthcare sub-sectors like gene therapy, medical technology, and biotechnology. Managed by Michael Taylor, it maintains 58 holdings and allocates about 91% of its portfolio to healthcare stocks, with small exposures to consumer cyclicals and industrials. Its largest positions include Eli Lilly and Co. (NYSE:LLY) at 8.15%, Humana (NYSE:HUM) at 8.08%, and Arcutis Biotherapeutics (NASDAQ:ARQT) at 6.60%. The fund was launched in 2021 and carries a currency hedge quirk. It has paid $0.30 per share over the trailing 12 months, which on its recent ~$39 share price works out to a 0.8% yield.

The Invesco Pharmaceuticals ETF focuses entirely on the U.S. pharmaceutical industry, providing concentrated exposure to companies involved in the research and manufacture of drugs. It currently holds 28 stocks and is classified as non-diversified. Its top holdings include AbbVie (NYSE:ABBV) at 5.87%, Gilead Sciences (NASDAQ:GILD) at 5.73%, and Pfizer (NYSE:PFE) at 5.58%. This fund was launched in 2005 and passively tracks a specific index rather than using active management. It has paid $1.13 per share over the trailing 12 months, which on its recent ~$123 share price works out to a 0.9% yield.

For more guidance on ETF investing, check out the full guide at this link.

Which looks like the better buy

Investors interested in healthcare exposure have very different choices in the Invesco Pharmaceuticals ETF (PJP) and Simplify Health Care ETF (PINK). For starters, the latter is actively-managed while PJP is a passive fund. Several additional factors may impact your decision to choose between these ETFs.

PINK donates its profits to the Susan G. Komen Foundation in the fight against breast cancer, so your investment contributes to this cause. It seeks to invest broadly across the healthcare sector without regard to company weightings in industry indices. Its expense ratio is lower, saving you money, and it is more diversified than PJP. However, its one-year and five-year returns are not as strong, and the fund has only existed since 2021, providing limited visibility into its performance over various macroeconomic cycles.

PJP seeks to replicate the performance of the Dynamic Pharmaceutical Intellidex Index, so its holdings reflect that. It's been around since 2005, providing over 20 years of history to help you gauge long-term returns. It's the ideal fund if you want exposure to domestic drugmakers and major pharmaceutical catalysts such as the GLP-1 weight-loss drugs. Yet that same focus can be a drawback if the pharma industry experiences a downturn.

Should you buy stock in Simplify Exchange Traded Funds - Simplify Health Care ETF right now?

Before you buy stock in Simplify Exchange Traded Funds - Simplify Health Care ETF, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Simplify Exchange Traded Funds - Simplify Health Care ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 15, 2026.

Robert Izquierdo has positions in Pfizer. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, Gilead Sciences, and Pfizer. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 11, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 11, 2026. Read on for the details.
Author  Mitrade
Nov 11, Wed
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 11, 2026. Read on for the details.
placeholder
Nvidia slid 7.7% after hours while AMD and Broadcom rose — the AI trade changed hands, it didn't breakNvidia closed Wednesday at 173.73, up 2.87%, then fell as much as 8.1% to 159.44 after reports that its board was preparing for a possible leadership change. The same session, the Philadelphia Semiconductor Index rose 5.7% with all 30 components higher, CoreWeave jumped 24.7% on 168% revenue growth, and Micron added 11.9%. If AI demand were being repriced, AMD and Broadcom would not be bid. This is a governance discount on one name, and 204.54 — the 200-day average — is the level that settles it.
Author  Irene Q.
Nov 12, Thu
Nvidia closed Wednesday at 173.73, up 2.87%, then fell as much as 8.1% to 159.44 after reports that its board was preparing for a possible leadership change. The same session, the Philadelphia Semiconductor Index rose 5.7% with all 30 components higher, CoreWeave jumped 24.7% on 168% revenue growth, and Micron added 11.9%. If AI demand were being repriced, AMD and Broadcom would not be bid. This is a governance discount on one name, and 204.54 — the 200-day average — is the level that settles it.
placeholder
Gold closed below $4,000 again — the ETF crowd and central banks stayed, the momentum money leftSpot gold is trading near $3,999, its third consecutive lower daily low, after a 5.00% 10-year yield and a 102.85 dollar index raised the odds of a December hike to 87%. But the selling is not coming from the strategic holders: managed-money net longs fell to 324 tonnes, a 21-week low, and Goldman Sachs attributes roughly 95% of five weeks of selling to non-reportable positions. ETFs still hold a record 4,256 tonnes and central banks bought 321 tonnes in Q3. The table below sets the triggers, directions and levels.
Author  Irene Q.
Nov 12, Thu
Spot gold is trading near $3,999, its third consecutive lower daily low, after a 5.00% 10-year yield and a 102.85 dollar index raised the odds of a December hike to 87%. But the selling is not coming from the strategic holders: managed-money net longs fell to 324 tonnes, a 21-week low, and Goldman Sachs attributes roughly 95% of five weeks of selling to non-reportable positions. ETFs still hold a record 4,256 tonnes and central banks bought 321 tonnes in Q3. The table below sets the triggers, directions and levels.
placeholder
Gold hit a one-year low while central banks bought 321 tonnes — the sellers were never the ones you thinkSpot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
Author  Irene Q.
Nov 13, Fri
Spot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
placeholder
Brent rose 3.3% and US crude stocks built 4.66 million barrels in the same weekBrent January settled at 95.82, up 3.3%, and WTI at 88.74, up 2.55%, after the US signalled it would not pursue a deal with Iran and attacks on Gulf shipping continued. In the same week, EIA data showed US crude inventories rising 4.657 million barrels against expectations of a 1.1 million draw, with gasoline up another 1.799 million. OPEC output also rebounded 1.96 million barrels a day to 27.16 million in October, led by Saudi Arabia at 10.56 million. This piece separates the geopolitical premium from the physical balance and lays out where each side of the trade is anchored.
Author  Irene Q.
Nov 13, Fri
Brent January settled at 95.82, up 3.3%, and WTI at 88.74, up 2.55%, after the US signalled it would not pursue a deal with Iran and attacks on Gulf shipping continued. In the same week, EIA data showed US crude inventories rising 4.657 million barrels against expectations of a 1.1 million draw, with gasoline up another 1.799 million. OPEC output also rebounded 1.96 million barrels a day to 27.16 million in October, led by Saudi Arabia at 10.56 million. This piece separates the geopolitical premium from the physical balance and lays out where each side of the trade is anchored.
goTop
quote